Matinas BioPharma Holdings, Inc. (MTNB)
Largest Insider Buys in Sector
MTNB Stock Price History Chart
MTNB Stock Performance
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular …
Insider Activity of Matinas BioPharma Holdings, Inc.
Over the last 12 months, insiders at Matinas BioPharma Holdings, Inc. have bought $0 and sold $0 worth of Matinas BioPharma Holdings, Inc. stock.
On average, over the past 5 years, insiders at Matinas BioPharma Holdings, Inc. have bought $102,650 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $16,600 was made by STERN ADAM K (director) on 2020‑08‑21.
List of Insider Buy and Sell Transactions, Matinas BioPharma Holdings, Inc.
| 2020-08-21 | director | 20,000 0.01% | $0.83 | $16,600 | +3.36% | |||
| 2020-05-14 | director | 100,000 0.0504% | $0.73 | $73,050 | +20.81% | |||
| 2020-03-17 | President and CEO | 10,000 0.0051% | $0.65 | $6,500 | +25.71% | |||
| 2020-03-17 | director | 10,000 0.0051% | $0.65 | $6,500 | +25.71% | |||
| 2019-11-25 | Chief Financial Officer | 58,000 0.0387% | $1.23 | $71,160 | -26.55% | |||
| 2019-11-22 | Chief Financial Officer | 36,500 0.0234% | $1.20 | $43,807 | -27.98% | |||
| 2019-11-15 | director | 100,000 0.0623% | $1.06 | $105,530 | -19.25% | |||
| 2019-08-20 | director | 20,000 0.0126% | $0.66 | $13,200 | +23.73% | |||
| 2019-08-19 | director | 10,400 0.0068% | $0.70 | $7,268 | +20.39% | |||
| 2019-08-19 | President and CEO | 14,650 0.0093% | $0.68 | $9,975 | +20.39% | |||
| 2019-08-19 | director | 20,000 0.0127% | $0.68 | $13,650 | +20.39% | |||
| 2019-08-16 | director | 100,000 0.0655% | $0.72 | $71,850 | +17.95% | |||
| 2019-06-14 | director | 15,000 0.0105% | $0.80 | $12,000 | +3.27% | |||
| 2019-06-12 | director | 20,000 0.0141% | $0.80 | $15,998 | +4.19% | |||
| 2019-06-12 | President and CEO | 12,487 0.0088% | $0.80 | $9,980 | +4.19% | |||
| 2019-06-10 | director | 15,000 0.0103% | $0.82 | $12,300 | -0.91% | |||
| 2019-06-07 | director | 20,000 0.0146% | $0.89 | $17,800 | -2.82% | |||
| 2019-05-31 | director | 80,000 0.0547% | $0.94 | $75,200 | -13.96% | |||
| 2019-05-16 | director | 150,000 0.1064% | $0.95 | $142,500 | -11.51% | |||
| 2019-05-16 | director | 25,000 0.018% | $0.96 | $24,115 | -11.51% |
Insider Historical Profitability
| Rongen Roelof | Chief Executive Officer | 3539416 69.5778% | $0.52 | 1 | 0 | <0.0001% |
| STERN ADAM K | director | 3301983 64.9103% | $0.52 | 12 | 0 | <0.0001% |
| MANNINO RAPHAEL J | Chief Scientific Officer | 1424565 28.0041% | $0.52 | 1 | 0 | <0.0001% |
| Jabbour Jerome D | President and CEO | 799511 15.7168% | $0.52 | 3 | 0 | +16.76% |
| Scibetta James S | director | 418309 8.2231% | $0.52 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $2.53M | 3.72 | 9.32M | 0% | +$0 | <0.0001 | |
| Sargent Investment Group Llc | $978,446.00 | 1.44 | 3.61M | -5.43% | -$56,232.53 | 0.23 | |
| BlackRock | $672,730.00 | 0.99 | 2.48M | -0.74% | -$5,043.58 | <0.0001 | |
| Geode Capital Management | $578,856.00 | 0.85 | 2.14M | +35.45% | +$151,512.34 | <0.0001 | |
| Arkadios Wealth Advisors | $440,104.00 | 0.65 | 1.62M | 0% | +$0 | 0.04 |